CollPlant Biotechnologies Raises $2 Million in Registered Direct Offering with Concurrent Warrant Placement

Collplant Holdings ( (CLGN) ) has shared an update.

On February 4, 2026, CollPlant Biotechnologies entered into a securities purchase agreement with institutional investors for a registered direct offering of 1,600,000 ordinary shares at $1.25 per share, alongside concurrent private placements of Series A and Series B warrants to purchase up to an additional 3,200,000 ordinary shares in total. The transaction, expected to close around February 6, 2026, is anticipated to generate approximately $2 million in gross proceeds, excluding any future warrant exercises, with the funds earmarked for general corporate purposes such as working capital and research and development. The company agreed to various issuance restrictions for 30 days, a one-year prohibition on variable rate transactions, and to file and pursue effectiveness of a registration statement for the resale of warrant shares, while H.C. Wainwright & Co. was engaged as exclusive placement agent and will receive cash fees and placement agent warrants. An Israeli legal opinion dated February 6, 2026, confirmed that the offered ordinary shares have been duly authorized and, upon delivery and payment, are or will be validly issued, fully paid and non-assessable under Israeli law.

The most recent analyst rating on (CLGN) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.

Spark’s Take on CLGN Stock

According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral.

The score is held down primarily by weak financial performance—large ongoing losses, heavy cash burn, and a shrinking equity base despite some TTM revenue and gross margin improvement. Technicals provide partial support with a stronger short-term trend, but longer-term trend and momentum are mixed. Valuation remains unattractive due to negative earnings and no dividend yield.

To see Spark’s full report on CLGN stock, click here.

More about Collplant Holdings

CollPlant Biotechnologies Ltd. is an Israel-based biotechnology company, listed in the U.S. as a foreign private issuer, that operates in the life sciences sector and focuses on developing products and technologies supported by ongoing research and development programs. The company funds its activities through public capital markets, including shelf registrations and direct offerings of ordinary shares and related securities to institutional and accredited investors.

Average Trading Volume: 40,580

Technical Sentiment Signal: Sell

Current Market Cap: $20.47M

See more data about CLGN stock on TipRanks’ Stock Analysis page.